10/6/2015 | CV | Theravance lowers conversion price of convertible notes due 2023
|
9/9/2015 | CV | Market Commentary: Dycom edges up in gray market; BroadSoft bringing new deal; Icahn bid for Vivus eyed
|
7/1/2015 | CV | Theravance lowers conversion price of convertible notes due 2023
|
2/23/2015 | CV | Market Commentary: Salix flat to lower in active trade after merger news; Spectrum sinks on patent ruling
|
12/23/2014 | CV | Theravance adjusts conversion rate of convertible notes due 2023
|
11/10/2014 | PP | Market Commentary: Dendreon drops after bankruptcy filing; Salix recoups some; Isis Pharmaceuticals on tap
|
11/10/2014 | CV | Market Commentary: Dendreon drops after bankruptcy filing; Salix recoups some; Isis Pharmaceuticals on tap
|
6/17/2014 | CV | Theravance adjusts conversion rate of 2.125% convertibles due 2023
|
5/19/2014 | CV | Theravance to adjust conversion rate of 2.125% convertibles due 2023
|
4/21/2014 | PV | New Issue: Theravance subsidiary closes private placement of $450 million 9% notes
|
12/31/2013 | CV | Outlook 2014: U.S. secondary market poised for continued strength, but investors eye Fed taper
|
10/25/2013 | CV | Market Commentary: NQ Mobile in focus after fraud allegations; Rayonier drops after earnings; AMR holds in
|
7/30/2013 | PP | Theravance negotiates $111.85 million private placement of its shares
|
6/5/2013 | CV | Market Commentary: Array adds a point in busy debut; market weaker; DDR off 0.25 point; Prologis in 0.5 point
|
6/4/2013 | CVLM | Theravance to redeem $172.5 million 3% convertibles under soft call
|
5/20/2013 | CV | Market Commentary: Tesla dips below par in volatile action; Theravance eyed; AMR surges despite lower shares
|
5/13/2013 | CV | Market Commentary: Endo Health 'comes in' on FDA news; Theravance still trades mixed; Shutterfly on deck
|
5/10/2013 | CV | Market Commentary: Theravance mixed on COPD drug approval; Meritor improves; Electronic Arts extends gains
|
4/29/2013 | CV | Market Commentary: Auxilium 'comes in' on disappointing quarter; Cemex slips on earnings; Theravance in focus
|
4/26/2013 | CV | Market Commentary: New Supernus jumps outright, adds on hedge; Theravance contracts on hedge; D.R. Horton up
|
4/25/2013 | CV | Market Commentary: PennyMac adds to 101; planned Supernus eyed; Microsoft adds; Theravance to split company
|
4/18/2013 | CV | Market Commentary: Intelsat adds outright; Theravance bonds mixed; Boston Properties' called bonds in focus
|
3/8/2013 | CV | Market Commentary: Theravance gains on hedge; Radian finds its footing; Smithfield jumps on potential split
|
3/4/2013 | CV | Market Commentary: Theravance up outright, flat to higher on hedge; Radian adds; Forestar, Hanwha improve
|
1/23/2013 | CV | Market Commentary: Planned KB Home adds in gray; newer Theravance still weak; Molycorp, OPKO, Auxilium on tap
|
1/22/2013 | CV | Theravance greenshoe lifts convertibles due 2023 to $287.5 million
|
1/18/2013 | CV | Market Commentary: Holiday weekend results in subdued trading; Theravance, Solazyme new issues lackluster
|
1/18/2013 | CV | New Issue: Theravance sells $250 million 10-year convertibles at 2.125%, up 32.5%
|
1/17/2013 | CV | Market Commentary: New Pacira surges on debut; planned Theravance seen cheap; planned Solazyme lacks borrow
|
1/16/2013 | CV | Market Commentary: InterMune notches stellar debut; Pacira sees revised terms; Cobalt steady dollar neutral
|
1/16/2013 | CV | Theravance to price $250 million 10-year convertibles to yield 2%-2.5%, up 27.5%-32.5%
|
7/11/2012 | CV | Market Commentary: Patriot Coal convertibles busy; Kodak gains on executive bonus plan; Theravance firms up
|
7/3/2012 | CV | Market Commentary: Convertibles quiet ahead of holiday; Lincare, Theravance extend gains; U.S. Steel better
|
4/4/2012 | CV | Market Commentary: SanDisk 1.5% convertibles come in on hedge; NetApp trades in line; Western Refining adds
|
4/3/2012 | CV | Market Commentary: Intel, Xilinx active, weaker as broader market reacts to FOMC minutes; Theravance better
|
4/2/2012 | PP | Theravance arranges $212.89 million private placement of common stock
|
1/30/2012 | CV | Market Commentary: Amylin active; Theravance better bid; MF Global 'comes in'; RadioShack warns on earnings
|
1/10/2012 | CV | Market Commentary: PHH's existing convertibles steady to higher on new deal launch; Kodak paper improves
|
2/4/2011 | CV | Market Commentary: Jaguar Mining gains; Hovnanian slips below par; Clearwire up on spectrum-purchase chatter
|
11/29/2010 | PP | Theravance pockets $129.38 million through private placement of shares
|
10/15/2010 | CV | Market Commentary: EMC holds gains; Western Refining extends gains; EnerSys up; new Alon issue doesn't price
|
3/30/2010 | CV | Market Commentary: Concur draws modest enthusiasm; Theravance; Navistar, Annaly Capital better; Ford down
|
7/23/2009 | CVHY | Theravance files $200 million shelf registering debt, stock, warrants
|
1/23/2008 | CV | Theravance greenshoe exercised, lifts 3% convertibles to $172.5 million
|
1/17/2008 | CV | Market Commentary: Citi upsizes; WaMu moves lower ahead of earnings; Theravance opens quietly higher
|
1/17/2008 | CV | New Issue: Theravance prices $150 million 3% convertible subordinated notes due 2015, up 30%
|
1/16/2008 | CV | Market Commentary: Intel down on earnings; Pioneer opens flat on falling oil; Transocean down; Citigroup deal drawing high bids
|
1/15/2008 | CV | Theravance launches $150 million convertible notes due 2015; talked at 2.75%-3.25%, up 25%-30%
|
1/15/2008 | CV | Market Commentary: Citigroup launches preferreds to help right ship; Pioneer on the way; UAL, Continental up on merger talk
|
4/19/2007 | SP | New Issue: ABN sells $2 million 25% knock-in notes linked to Theravance
|
4/13/2007 | SP | Market Commentary: Lehman to price notes linked to Israeli shekel; Barclays plans S&P 500-linked notes
|
4/3/2007 | SP | ABN Amro to price 25% reverse convertibles linked to Theravance via LaSalle
|
4/3/2007 | SP | Market Commentary: ABN Amro, Rabo to price slate of reverse convertibles with big coupons
|
10/27/2006 | BT | Theravance maintained at buy by Merrill
|
10/26/2006 | BT | Theravance net loss for the quarter unchanged from prior-year period
|
10/11/2006 | BT | Theravance plans New Drug Application for telavancin by year end
|
10/10/2006 | BT | Theravance reiterated at buy by Merrill
|
9/20/2006 | BT | Theravance could earn $445 million in milestones as beta2 agonists enter phase 2b clinical trials
|
8/23/2006 | BT | Theravance reiterated at buy by Merrill
|
8/22/2006 | BT | Market Commentary: Protalix gets $15 million investment as part of merger; Theravance sees positive telavancin trial results
|
8/22/2006 | BT | Theravance: telavancin showed better clinical cure rate of skin infections than vancomycin in Atlas trials
|
7/28/2006 | BT | Merrill rates Theravance at buy
|
7/24/2006 | BT | Merrill maintains Theravance at buy
|
7/18/2006 | BT | Theravance at buy by Merrill
|
7/18/2006 | BT | Theravance, Astellas add Japan to collaboration on investigational antibiotic
|
6/28/2006 | BT | Rodman & Renshaw begin coverage of Theravance at market outperform
|
6/19/2006 | BT | Merrill puts Theravance at buy
|
6/12/2006 | BT | Merrill rates Theravance at buy
|
5/16/2006 | BT | Merrill maintains Theravance at buy
|
5/16/2006 | BT | Theravance completes enrollment in phase 3 clinical program with antibiotic telavancin
|
4/28/2006 | BT | Merrill keeps Theravance at buy
|
4/21/2006 | BT | Merrill maintains Theravance at buy
|
4/20/2006 | BT | Theravance to start phase 2b clinical program with beta agonist for asthma
|
2/10/2006 | BT | Merrill reiterates Theravance at buy
|
2/2/2006 | BT | Market Commentary: Valera debut shares gain 10%; Theravance up; ImClone sinks; Nabi rockets; Teva pressured
|
2/1/2006 | BT | New Issue: Theravance prices $131.1 million follow-on sale of stock at $28.50
|
1/30/2006 | BT | Theravance plans follow-on of 4.6 million shares via Merrill, HSBC, Thomas Weisel
|
1/30/2006 | BT | Market Commentary: Theravance at bat; Amylin dives; Nektar reverses; CV Therapeutics takes a hit; First Horizon higher
|
1/11/2006 | BT | Merrill raises Theravance price target to $32
|
1/5/2006 | BT | Market Commentary: Advancis sale of Keflex stumbles; Nuvelo spikes on Bayer pact; buyers snap up Nektar, MannKind
|
1/5/2006 | BT | Theravance reiterated by Merrill at buy
|
12/21/2005 | BT | Theravance's telavancin antibiotic kills Staph infection in 96% of patients, study says
|
11/21/2005 | BT | Theravance still a buy, Merrill Lynch says
|
11/8/2005 | BT | Merrill Lynch reiterates Theravance at buy
|
10/28/2005 | BT | Merrill Lynch drops Theravance target to $29
|
7/27/2005 | BT | Theravance upped by Merrill Lynch to buy
|
7/27/2005 | BT | Market Commentary: Theravance rises; NPS Pharma off; Advanced Life Sciences IPO on for Thursday; Elan, Biogen slightly higher
|